Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


UNIVERSITY OF LEICESTER

Leicestershire, GB

UNIVERSITY OF LEICESTER Patent applications
Patent application numberTitlePublished
20120130017PROCESS AND NEW COMPOUNDS - There is provided a novel process for preparing polyamides (in particular cyclic and hairpin polyamides) comprising the step of coupling an amine with a Boc-protected amino acid monomer in the presence of diphosgene and/or triphosgene. Such a process may be performed on a solid or solution phase.05-24-2012
20110091450METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.04-21-2011
20100184126 SAMPLING DEVICE - A portable sampling device (07-22-2010
20100144544FLUORESCENCE LABELLING - Fluorescence Labelling This invention generally relates to techniques for fluorescence labelling, and to methods, apparatus and computer program code for processing fluorescence signal data. A method of determining respective first and second degree-of-labelling signals for different respective first and second fluorophores associated with a common entity, the method comprising: determining a first fluorescence signal from said first and second fluorophores under first conditions; determining a second fluorescence signal from said first and second fluorophores under second conditions different to said first conditions; and determining said first and second degree-of-labelling signals for said first and second fluorophores from said first and second fluorescence signals; and wherein said determining of said first and second degree-of-labelling signals is responsive to at least one coupling value (c06-10-2010
20100099132BACTERIAL GROWTH INDUCER - The present invention relates to methods of preparing bacterial growth inducers, and in particular to novel bacterial growth inducers/resuscitators prepared by such methods. The invention extends to various applications of such growth inducers, for example in clinical and environmental diagnostics, in reviving not immediately culturable (NIC) bacteria, and in the analyses of microbial populations in blood, food and soil samples.04-22-2010
20100075969Angiogenesis - The invention provides medicaments comprising an agent, which selectively modulates β2-adrenergic receptor conformation, or receptor activity, or activation thereof. The medicaments may be used for treating diseases that are characterised by disorganized and/or abnormal vasculature, such as cancer and metastatic disease. The medicaments may also be used for promoting organized/normal branched vasculature.03-25-2010
20100032568DETECTION OF THE ENERGY OF PHOTONS FROM BIOLOGICAL ASSAYS - A cryogenic detector is used for detection in a biological assay.02-11-2010
20090325867RECEPTOR-SPECIFIC TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) VARIANTS - The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and/or 199V; preferably also 201R, 213W and 215D, and/or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same.12-31-2009
20090205058GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS - Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.08-13-2009
20090194426EUTECTIC MIXTURES BASED UPON MULTIVALENT METAL IONS - There is provided a mixture having a freezing point of up to 50° C., formed by reaction between: (A) one molar equivalent of a salt of formula I (M08-06-2009

Patent applications by UNIVERSITY OF LEICESTER